Reltecimod
Cat. No.: IBDI-438586
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
Product Details
Target |
Bacterial | CD28 |
Molecular Weight |
1037.19 |
Synonyms |
AB-103 |
Sequence Shortening |
ASPMLVAYDA |
Storage & Handling
Shipping |
Room temperature in continental US. May vary elsewhere. |
Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.